Clovis strikes 3B deal to move into radiopharmaceuticals

Clovis Oncology has paid $12 million for rights to FAP-targeted radiopharmaceuticals in development at 3B Pharmaceuticals. The deal gives Clovis the ex-Europe rights to a cancer candidate set to enter the clinic in the second half of next year.